Tremfya Dosing Schedule
Tremfya (guselkumab) is administered as 100 mg subcutaneous injection at week 0, week 4, and then every 8 weeks thereafter for plaque psoriasis and psoriatic arthritis. 1, 2
Standard Dosing Regimen
The FDA-approved and guideline-recommended dosing schedule is straightforward:
- Loading doses: 100 mg at week 0 and week 4
- Maintenance: 100 mg every 8 weeks (Q8W) starting at week 12 1, 2
This represents a Grade A recommendation from the Joint AAD-NPF Guidelines of Care, indicating the highest level of evidence supporting this regimen 1.
Self-Administration
Tremfya can be self-administered by patients using prefilled syringes, prefilled pens, or One-Press patient-controlled injectors 2. This convenient dosing schedule (every 8 weeks after the initial loading phase) is often preferred by patients compared to biologics requiring more frequent administration 1.
Alternative Dosing for Specific Conditions
Psoriatic Arthritis at High Risk of Joint Damage
For patients with psoriatic arthritis at high risk of structural damage progression, guselkumab 100 mg every 4 weeks (Q4W) has been approved in Europe and shows effectiveness in real-world practice 3. This intensified schedule achieved DAPSA remission in 55.6% and MDA in 77.8% of high-risk patients at 24 weeks 3.
Ulcerative Colitis
For moderate-to-severe ulcerative colitis, the dosing differs:
- Induction: 200 mg IV at weeks 0,4, and 8
- Maintenance: Either 100 mg subcutaneous Q8W or 200 mg subcutaneous Q4W 2, 4
Treatment Interruption and Reinitiation
If treatment is temporarily discontinued (e.g., for febrile illness requiring antibiotics):
- Consider repeating loading doses if the patient is flaring and/or if more than 3-4 half-lives have passed since the previous dose 1
- Given guselkumab's half-life of 15-18 days, this translates to approximately 45-72 days 2
- The necessity of repeating loading doses depends on disease severity and number of missed doses 1
Clinical Pearls
Response assessment: Definitive response to guselkumab should be evaluated after 12 weeks of continuous therapy 1. This aligns with the first maintenance dose timing.
Dose adjustment: No dose adjustment is needed based on age (≥65 years) or body weight, despite pharmacokinetic differences 2. The standard 100 mg Q8W regimen maintains therapeutic serum concentrations (approximately 1.2 mcg/mL at steady state) across patient populations 2.
Biomarker-guided dosing: Phase 2 data showed that steady-state trough concentrations ≥0.67 μg/mL were associated with optimal efficacy (PGA 0/1: 90%, PGA 0: 70%), and 72.5% of Phase 3 patients achieved this target with the 100 mg Q8W regimen 5.